Summary
AbbVie Inc. reported a revenue decrease of 7.2% to $26.1 billion for the first six months of 2023, compared to the same period in 2022. This decline was primarily driven by the loss of exclusivity for Humira in the U.S., which saw a significant revenue drop. Despite the overall revenue dip, AbbVie demonstrated strong growth in key immunology products like Skyrizi and Rinvoq, which saw substantial year-over-year increases. The company also reported a decrease in net earnings attributable to AbbVie Inc. to $2.26 billion for the first six months of 2023, down from $5.41 billion in the prior year, impacted by factors including amortization of intangibles, changes in contingent consideration, and an intangible asset impairment charge. AbbVie continues to invest in its pipeline and manage its capital through dividends and share repurchases. The company's financial position remains solid with $8.76 billion in cash and equivalents as of June 30, 2023. AbbVie maintained a strong operating cash flow of $10.5 billion for the first six months of the year. Management highlighted strategic objectives including maximizing its diversified revenue base, leveraging commercial strength, investing in its pipeline, and returning cash to shareholders. The company also amended and restated its revolving credit facility, increasing commitments to $5.0 billion, indicating continued financial flexibility.
Financial Highlights
56 data points| Revenue | $13.87B |
| Cost of Revenue | $4.24B |
| Gross Profit | $9.63B |
| SG&A Expenses | $3.27B |
| Operating Expenses | $9.35B |
| Operating Income | $4.51B |
| Interest Expense | $552.00M |
| Net Income | $2.02B |
| EPS (Basic) | $1.14 |
| EPS (Diluted) | $1.14 |
| Shares Outstanding (Basic) | 1.77B |
| Shares Outstanding (Diluted) | 1.77B |
Key Highlights
- 1AbbVie's net revenues for the first six months of 2023 decreased by 7.2% to $26.1 billion, primarily due to the U.S. loss of exclusivity for Humira.
- 2Skyrizi and Rinvoq demonstrated strong growth, with net revenues increasing by 48% and 51.7%, respectively, for the six-month period, indicating successful market penetration and uptake.
- 3Net earnings attributable to AbbVie Inc. significantly decreased to $2.26 billion for the first six months of 2023, compared to $5.41 billion in the prior year, influenced by substantial non-cash charges such as amortization of intangibles and impairment charges.
- 4Operating cash flow remained robust, totaling $10.5 billion for the first six months of 2023, underscoring the company's strong cash generation capabilities.
- 5AbbVie repurchased $1.6 billion of its shares in the first six months of 2023 and declared dividends totaling $5.3 billion, demonstrating a commitment to returning capital to shareholders.
- 6The company amended its revolving credit facility, increasing commitments to $5.0 billion and extending the maturity to March 2028, enhancing financial flexibility.
- 7An intangible asset impairment charge of $630 million was recorded in the first quarter of 2023 related to the R&D plan revision for AGN-151607.